Upstream Bio (NASDAQ: UPB) recently received a number of ratings updates from brokerages and research firms:
- 8/15/2026 – Upstream Bio was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 8/14/2026 – Upstream Bio had its price target raised by JPMorgan Chase & Co. from $8.00 to $9.00. They now have a “neutral” rating on the stock.
- 8/11/2026 – Upstream Bio had its price target lowered by Truist Financial Corporation to $25.00. They now have a “buy” rating on the stock.
- 8/3/2026 – Upstream Bio had its “sell (e+)” rating reaffirmed by Weiss Ratings.
Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.
The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.
See Also
- Five stocks we like better than Upstream Bio
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Upstream Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.
